Title: A randomized, placebo-controlled, double-blind Phase 3 trial comparing, relative to placebo, the effect of Kinisoquin on thromboembolic events in patients with metastatic pancreatic cancer (CATIQ P3)

Brief Title: The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Brief Summary: The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin as compared to the placebo in prevention of thromboembolic events in patients with metastatic pancreatic cancer.

Title: Novel Mechanism for Cancer Associated Thrombosis

Brief Title: Multiomic Analysis of CAT

Title: An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia

Brief Title: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Brief Summary: The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Title: Evaluating Platelet Drp1 Phosphorylation in Patients With Heparin Induced Thrombocytopenia

Brief Title: Evaluating Platelet Drp1 Phosphorylation in Patients With HIT

Title: Splanchnic Venous Thrombosis Outcomes in patients with Myeloproliferative Neoplasms

Brief Title: Splanchnic Venous Thrombosis Outcomes in Myeloproliferative Neoplasms

Title: A Phase 2 study of ruxolitinib in low-risk essential thrombocythemia and polycythemia vera with significant symptom burden

Brief Title: Ruxolitinib in Thrombocythemia and Polycythemia Vera

Brief Summary: This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). - This research study involves the study drug Ruxolitinib.

Title: RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer

Brief Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Brief Summary: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer